• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 5, 2011

View Archived Issues

Opportunity vs. Vulnerability in New Fundraising Initiatives

It seems increasingly likely that at least some of Congress's capital formation bills will soon become law, and that those laws will bode well for private biotechs by creating new fundraising pathways. Read More

Unbiased Sequencing Speed, Price Now Realistic For Clinic

Testing for specific mutations has already entered the clinical oncology landscape. Cancer drugs such as Zelboraf (vemurafenib, Roche AG and Daiichi Sankyo Co. Ltd.) and Xalkori (crizotinib, Pfizer Inc.) target patients with specific mutations. Earlier in development, some clinical trials, such as for Exelixis Inc.'s cabozantinib, have focused on specific mutations across a variety of tumor types. Read More

Money Raised By Biotech In 2011 Vs. 2010

Read More

Arrowhead, Others Keep the RNAi Faith Despite Doubters

It's been a tough few years for RNAi. Last fall, Roche AG discontinued its preclinical RNAi work, and Novartis AG declined to expand an RNAi partnership with Alnylam Pharmaceuticals Inc. Pfizer Inc. followed suit earlier this year, closing its oligonucleotide therapeutics unit. Read More

Money Raised By Biotech: Jan. 1 - Dec. 2, 2011

Read More

Week in Review

FinancingsArGen-X BV raised $37.1 million in a Series B round.Celsion Corp. is raising $15 million in a private placement of stock and warrants.Inhibitex Inc. raised $20 million through an at-the-market offering.NuCana BioMed Ltd. raised $10.5 million in a Series A round for anticancer nucleoside analogues.Oxigene Inc. established a $20 million standby equity purchase agreement. Read More

Word on the Street

"I looked at it as the best cost of capital to get this product approved."– Marc Beer, CEO of Aegerion Pharmaceuticals Inc., on his firm's initial public offering, which came at a discount to the original price range"That's why you hear the words 'friends and family.' Whether it's a physical community, an Internet community – one way or another, the relationship has to exist."– David Schechner, managing director at Canaccord Genuity Inc., on how retail investors like to invest in companies with which they have a relationship Read More

Week in Washington

An FDA advisory committee is evaluating ways to make the toughest risk evaluation and mitigation strategies more effective and less burdensome.The Senate unanimously approved an amendment to the National Defense Authorization Act that would fund Small Business Innovation and Research and Small Business Technology Transfer through fiscal 2019. Read More

Public Financing Of Biotechnology: November 2011

I. COMMENCED TRADING IN NOVEMBERCompany (Symbol)#Date FiledDateComm.Shares/Units (M)PriceSharesOut (M)@Lead, OtherUnderwriters Read More

Biotech Money Raised By Month In 2011: Jan. - Nov.

Type of financingJanFebMarAprMayJunJulAugSepOctNovTotal ($M)Public offerings711.7 Read More

Other Financings Of Public Biotechnology Companies: November 2011

TOTAL: $338.797MCompany (Location)Type Of FinancingNumber OfShares, UnitsOr Warrants (M)AmountRaised (M)Investors; Placement Agents; Details (Date) Read More

Top Private Financings Of Public Companies: 2011

CompanyMonthAmount RaisedAmgen Inc.June$3BEndo Pharmaceuticals Holdings Inc.May$900MValeant Pharmaceuticals International Inc.February$650MDendreon Corp.January$620MRegeneron Pharmaceuticals Inc. Read More

Venture Capital And Other Investments In Private Biotechnology Companies: November 2011

Total: $394MCompanyLocationDateAmt. (M)DetailsAffiris AGVienna, Austria11/9€25 ($34) Read More

Top Financings Of Private Companies: 2011

CompanyMonthAmount RaisedPro Bono BioSeptember$600MH3 BiomedicineJanuary$200MSymphogenJanuary$131MTesaroJune$101MAscletisApril$100MIntrexon Read More

Milestone Payments From Corporate Partners: Nov. 2011

Total: $39MYear to Date: $544.091MCompany (Location)Partner (Location)Amt.(M)Details (Date)Affitech A/S (Copenhagen, Denmark)IBC Generium (Russia)€2 ($2.7) Read More

BioWorld Stock Index 2011

Read More

Nasdaq Stock Index 2011

Read More

Stock Gainers and Losers For The Week

Read More

BioWorld Stock Report For Public Biotechnology Companies

Read More

FDA Approvals In November

CompanyDrugIndicationBristol-Myers Squibb Co.ErbituxHead and neck cancerEUSA Pharma Inc.ErwinaseAcute lymphoblastic leukemiaIncyte Corp.JakafiMyelofibrosisIntelGenx Corp. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • DNA double helix under a magnifying glass

    23andme genetic privacy concerns garner Congressional scrutiny

    BioWorld MedTech
    The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe